Literature DB >> 25201169

A qualitative study of the impact of severe asthma and its treatment showing that treatment burden is neglected in existing asthma assessment scales.

Michael E Hyland1, Ben Whalley, Rupert C Jones, Matthew Masoli.   

Abstract

BACKGROUND: People with severe asthma experience significant respiratory symptoms and suffer adverse effects of oral corticosteroids (OCS), including disturbed mood and physical symptoms. OCS impacts on health-related quality of life (HRQoL) have not been quantified. Asthma HRQoL scales are valid as outcome measures for patients requiring OCS only if they assess the deficits imposed by OCS. AIMS: The aim of this study was to compare the burden of disease and treatment in patients with severe asthma with items in eight asthma-specific HRQoL scales.
METHODS: Twenty-three patients with severe asthma recruited from a severe asthma clinic were interviewed about the impact of their respiratory symptoms and the burden of their treatment. The domains from a thematic analysis of these interviews were compared with the items of eight asthma-specific HRQoL scales.
RESULTS: In addition to the burden caused by symptoms, ten domains of OCS impact on HRQoL were identified: depression, irritability, sleep, hunger, weight, skin, gastric, pain, disease anxiety, and medication anxiety. Some patients experienced substantial HRQoL deficits attributed to OCS. Although all HRQoL scales include some OCS-relevant items, all eight scales fail to adequately assess the several types of burden experienced by some patients while on OCS.
CONCLUSION: The burden of OCS in severe asthma is neglected in policy and practice because it is not assessed in outcome studies. Existing asthma HRQoL scales provide an overly positive estimation of HRQoL in patients with frequent exposure to OCS and underestimate the benefit of interventions that reduce OCS exposure. Changes to existing measurement procedures are needed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25201169     DOI: 10.1007/s11136-014-0801-x

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  27 in total

1.  Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.

Authors:  H Milgrom; R B Fick; J Q Su; J D Reimann; R K Bush; M L Watrous; W J Metzger
Journal:  N Engl J Med       Date:  1999-12-23       Impact factor: 91.245

2.  Treatment of chronic asthma with prednisolone; significance of eosinophils in the sputum.

Authors:  H M BROWN
Journal:  Lancet       Date:  1958-12-13       Impact factor: 79.321

3.  A scale for the measurement of quality of life in adults with asthma.

Authors:  G B Marks; S M Dunn; A J Woolcock
Journal:  J Clin Epidemiol       Date:  1992-05       Impact factor: 6.437

4.  A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire.

Authors:  P W Jones; F H Quirk; C M Baveystock; P Littlejohns
Journal:  Am Rev Respir Dis       Date:  1992-06

Review 5.  Measuring asthma-specific quality of life: structured review.

Authors:  C J Apfelbacher; M Hankins; P Stenner; A J Frew; H E Smith
Journal:  Allergy       Date:  2010-11-08       Impact factor: 13.146

6.  Development and validation of the Mini Asthma Quality of Life Questionnaire.

Authors:  E F Juniper; G H Guyatt; F M Cox; P J Ferrie; D R King
Journal:  Eur Respir J       Date:  1999-07       Impact factor: 16.671

7.  Patients' views on asthma-specific quality of life questionnaires: qualitative interview study in Germany.

Authors:  Christian Apfelbacher; Melanie Weiss; Joachim Saur; Helen Smith; Adrian Loerbroks
Journal:  J Asthma       Date:  2012-08-22       Impact factor: 2.515

8.  The prevalence of nonadherence in difficult asthma.

Authors:  Jacqueline Gamble; Michael Stevenson; Elizabeth McClean; Liam G Heaney
Journal:  Am J Respir Crit Care Med       Date:  2009-07-30       Impact factor: 21.405

9.  Mood and Cognitive Changes During Systemic Corticosteroid Therapy.

Authors:  E Sherwood Brown; Patricia A. Chandler
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2001-02

10.  Difficult asthma: people's perspectives on taking corticosteroid therapy.

Authors:  Jacqueline Gamble; Donna Fitzsimons; Dave Lynes; Liam Gabriel Heaney
Journal:  J Clin Nurs       Date:  2007-03       Impact factor: 3.036

View more
  35 in total

1.  Topical 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibition Corrects Cutaneous Features of Systemic Glucocorticoid Excess in Female Mice.

Authors:  Ana Tiganescu; Melanie Hupe; Yoshikazu Uchida; Theadora Mauro; Peter M Elias; Walter M Holleran
Journal:  Endocrinology       Date:  2018-01-01       Impact factor: 4.736

Review 2.  Role of Biologics in Asthma.

Authors:  Mary Clare McGregor; James G Krings; Parameswaran Nair; Mario Castro
Journal:  Am J Respir Crit Care Med       Date:  2019-02-15       Impact factor: 21.405

Review 3.  Use of Health Related Quality of Life in Clinical Trials for Severe Asthma: A Systematic Review.

Authors:  Joseph W Lanario; Lorna Burns
Journal:  J Asthma Allergy       Date:  2021-08-12

4.  A Renewed Charter: Key Principles to Improve Patient Care in Severe Asthma.

Authors:  Andrew Menzies-Gow; David J Jackson; Mona Al-Ahmad; Eugene R Bleecker; Francisco de Borja G Cosio Piqueras; Stephen Brunton; Giorgio Walter Canonica; Charles K N Chan; John Haughney; Steve Holmes; Janwillem Kocks; Tonya Winders
Journal:  Adv Ther       Date:  2022-10-17       Impact factor: 4.070

5.  Health-related quality of life associated with systemic corticosteroids.

Authors:  Patrick W Sullivan; Vahram H Ghushchyan; Gary Globe; Brandon Sucher
Journal:  Qual Life Res       Date:  2016-10-18       Impact factor: 4.147

6.  Treatment Burden and Chronic Illness: Who is at Most Risk?

Authors:  Adem Sav; Jennifer A Whitty; Sara S McMillan; Elizabeth Kendall; Fiona Kelly; Michelle A King; Amanda J Wheeler
Journal:  Patient       Date:  2016-12       Impact factor: 3.883

7.  The Severe Asthma Questionnaire: sensitivity to change and minimal clinically important difference.

Authors:  Matthew Masoli; Joseph W Lanario; Michael E Hyland; Andrew Menzies-Gow; Adel H Mansur; David Allen; James W Dodd; Gemma Hayes; Jose M Valderas; Sarah E Lamb; Rupert C Jones
Journal:  Eur Respir J       Date:  2021-06-17       Impact factor: 16.671

Review 8.  Oral corticosteroids stewardship for asthma in adults and adolescents: A position paper from the Thoracic Society of Australia and New Zealand.

Authors:  John Blakey; Li Ping Chung; Vanessa M McDonald; Laurence Ruane; John Gornall; Chris Barton; Sinthia Bosnic-Anticevich; John Harrington; Mark Hew; Anne E Holland; Trudy Hopkins; Lata Jayaram; Helen Reddel; John W Upham; Peter G Gibson; Philip Bardin
Journal:  Respirology       Date:  2021-09-29       Impact factor: 6.175

9.  Long-acting muscarinic antagonist use in adults with asthma: real-life prescribing and outcomes of add-on therapy with tiotropium bromide.

Authors:  David Price; Alan Kaplan; Rupert Jones; Daryl Freeman; Anne Burden; Shuna Gould; Julie von Ziegenweidt; Muzammil Ali; Christine King; Mike Thomas
Journal:  J Asthma Allergy       Date:  2015-01-14

Review 10.  Approach to Patients with Severe Asthma: a Consensus Statement from the Respiratory Care Experts' Input Forum (RC-EIF), Iran.

Authors:  Khalil Ansarin; Davood Attaran; Hamidreza Jamaati; Mohammad Reza Masjedi; Hamidreza Abtahi; Ali Alavi; Masoud Aliyali; Amir Mohammad Hashem Asnaashari; Reza Farid-Hosseini; Seyyed Mohammad Ali Ghayumi; Hassan Ghobadi; Atabak Ghotb; Abolhassan Halvani; Abbas Nemati; Mohammad Hossein Rahimi Rad; Masoud Rahimian; Ramin Sami; Hamid Sohrabpour; Sasan Tavana; Mohammad Torabi-Nami; Parviz Vahedi
Journal:  Tanaffos       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.